The first cancer virotherapy medicine
RIGVIR® contains a live non-pathogenic ECHO-7 virus that has not been genetically modified. RIGVIR® is oncotropic and oncolytic. It finds and selectively infects tumour cells.
Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment, which improves progression time, survival and the quality of life of cancer patients. RIGVIR® is well tolerated and does not cause serious adverse effects. The most common side effect is a subfebrile temperature for 1-3 days. This is reversible and does not require treatment.
RIGVIR® is the first oncolytic virotherapy medicine that has been approved for cancer treatment and that has been introduced into medical practice. RIGVIR® was approved in Latvia in 2004 for cutaneous melanoma therapy. Since 2011 RIGVIR® is fully reimbursed by the state for residents of Latvia and from 2015 it has been included in the guidelines for skin cancer and melanoma treatment. In 2015 RIGVIR® was approved in Georgia and since 2016 it has been approved in Armenia.
RIGVIR® Mode of action
RIGVIR® finds and infects tumour cells. This process is called oncotropism. Subsequently, RIGVIR® replicates in tumour cells and destroys them. This process is called oncolysis. Both processes, oncotropism and oncolysis, are selective for tumour cells and healthy cells are only minimally affected, if at all.
RIGVIR® is administered as a series of injections according to virotherapy treatment protocols. Virotherapy treatment usually takes roughly 3 years. It’s important to consult with a certified virotherapy specialist to achieve the best possible treatment result. Virotherapy is usually an ambulatory care treatment, which only has mild side effects. The most common side effect is a subfebrile temperature lasting 1-3 days.
Oncolytic virotherapy throughout the world is cooridnated by the International Virotherapy Center (IVC). The mission of the International Virotherapy Center is to provide virotherapy treatment to every cancer patient who needs it. The main activities of IVC are focused on the training and certification of doctors, the accreditation of medical institutions and the coordination of patient treatment abroad.
RIGVIR® oncolytic virotherapy has already been administered to patients in more than 50 countries.
For more information on virotherapy treatment, please contact the International Virotherapy Center: www.virotherapy.eu